F23 F20-F29 F05.9 F10-F19 F00-F09 T44
Conditions
Interventions
Group 1: Persons with a so-called acute psychotic syndrome are to be included (i.e. characteristic changes in behaviour and perception with formal and substantive thought disorders, hallucinations) e.
Sponsors
Klinik für Psychiatrie und Psychotherapie der Charité - Universitätsmedizin Berlin
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Prerequisite for inclusion in the register study is the ability to consent - Written consent to participation - Persons with a so-called acute psychotic syndrome should be included (i.e. characteristic changes in behavior and perception with formal and content-related thought disorders, hallucinations), e.g. in connection with - neurodegenerative diseases - Autoimmune encephalopathies - drug or intoxication-related delirium - metabolic delirium - Alcohol Withdrawal delirium - postoperative delirium - acute polymorphic schizophreniform disorder - schizophrenia - schizoaffective disorder
Exclusion criteria
Exclusion criteria: - Withdrawal of consent to participate in the study - Severe diseases with a poor prognosis or complex constellations of diseases with numerous comorbidities [e.g. terminal renal failure, liver failure, therapy-resistant diabetes mellitus or epilepsy, permanent severe impairment of cognitive function, Mini-Mental Status Test (MMST) <13].
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of the planned registry study is to use machine learning methods [in particular sparse canonical correlation analysis (sCCA) as well as convolutional neural networks (CNN) and Bayesian networks (BN)] to identify correlations between psychopathological symptoms on the one hand and imaging and physiological parameters (Ethiopathogenesis) on the other hand. | — |
Secondary
| Measure | Time frame |
|---|---|
| Based on the identified statistical relations, corresponding parameters will be evaluated with regard to their predictive value for the clinical course of psychotic symptoms. In addition, the register study will allow the calculation of epidemiological parameters and their relation to the course of disease and therapy. | — |
Countries
Germany
Contacts
Public ContactSurjo Soekadar
AG Klinische Neurotechnologie der Klinik für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin
Outcome results
None listed